Though simple and attractive, the role of hydration for the prophylaxis of contrast nephrotoxicity has not been definitively established. We prospectively evaluated the role of deliberate saline hydration in patients undergoing nonemergency cardiac catheterization. Patients (n = 53) were randomized on the day prior to scheduled catheterization to one of two groups – group 1 (n = 27) received normal saline for 24 h (at a rate of 1 ml/kg/h) beginning 12 h prior to scheduled catheterization, and group 2 (n = 26) were allowed unrestricted oral fluids. Serum creatinine measured 24 and 48 h postcardiac catheterization was compared to the pre-randomization baseline value. The mean baseline calculated creatinine clearance was 79.6 ± 31.9 ml/min and the mean baseline creatinine was 106 ± 28 µmol/l. An increase in serum creatinine by at least 44.2 µmol/l (0.5 mg/dl), within 48 h of contrast exposure, was considered to represent clinically significant acute renal insufficiency. Ten subjects (18.9%) developed acute renal insufficiency. The incidence of acute renal insufficiency was significantly lower in group 1 (1 out of 27) as compared to group 2 (9 out of 26; p = 0.005 for comparison between groups; relative risk 0.11, 95% confidence interval 0.015 to 0.79). Twenty-four hours after contrast exposure, the mean increase in creatinine was less in group 1 vs. group 2 (8 ± 11 vs. 20 ± 21 µmol/l, p = 0.02). The increase in creatinine was not significantly different in group 1 vs. group 2 48 h after contrast exposure (12 ± 21 vs. 29 ± 40 µmol/l, p = 0.17). Deliberate saline hydration decreases the incidence of contrast-related acute renal failure and the severity of contrast-induced renal dysfunction in patients undergoing non-emergency cardiac catheterization.

Keywords:
Kidney failure, acute, Contrast therapy, Fluid therapy
1.
Barrett BJ: Contrast nephrotoxicity. J Am Soc Nephrol 1994;5:125–137.
2.
Murphy SW, Barrett BJ, Parfrey PS: Contrast nephropathy. J Am Soc Nephrol 2000;11:177–182.
3.
Barrett BJ, Parfrey PS: Prevention of nephrotoxicity of radiocontrast agents. N Engl J Med 1994;331:1449–1450.
4.
Teruel JL, Marcen R, Herrero JA, Ortuno FJ: An easy and effective procedure to prevent radiocontrast agent nephrotoxicity in high-risk patients. Nephron 1989;282.
5.
Eisenberg RL, Bank WO, Hedgock MW: Renal failure after major angiography can be avoided with hydration. Am J Radiol 1981;6:859–861.
6.
Weisberg LS, Kurnik PB, Kurnik BRC: Risk of radiocontrast nephropathy in patients with and without diabetes mellitus. Kidney Int 1994;45:259–265.
7.
Solomon R, Werner C, Mann D, et al: Effects of saline, mannitol, and furosemide on acute decreases in renal function caused by radiocontrast agents. N Engl J Med 1994;331:1416–1420.
8.
Weinstein J-M, Heyman S, Brezis M: Potential deleterious effect of furosemide in radiocontrast nephropathy. Nephron 1992;62:413–415.
9.
Ghandour F, Larranaga J, Menon A, et al: The effect of mannitol (M) on the development of contrast-associated nephropathy (CAN) in patients with chronic renal insufficiency. J Am Soc Nephrol 1995;6:464.
10.
Tepel M, Van der Giet M, Schwarzfeld C, et al: Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000;343:180–184.
11.
Rich MW, Crecelius CA: Incidence, risk factors, and clinical course of acute renal insufficiency after cardiac catheterization in patients 70 years of age or older. Arch Intern Med 1990;150:1237–1242.
12.
Parfrey PS, Griffiths SM, Barrett BJ, et al: Contrast-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. A prospective controlled study. N Engl J Med 1989;320:143–149.
13.
Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31–41.
14.
Abizaid AS, Clark CE, Mintz GS, et al: Effects of dopamine and aminophylline on contrast-induced acute renal failure after coronary angioplasty in patients with pre-existing renal insufficiency. Am J Cardiol 1999;83:260–263.
15.
Schwab SJ, Hlatky MA, Pieper KS, et al: Contrast nephrotoxicity: A randomized trial of a nonionic and an ionic radiographic contrast agent. N Engl J Med 1989;320:149–153.
16.
Davidson CJ, Hlatky M, Morris KG, et al: Cardiovascular and renal toxicity of a nonionic radiographic contrast agent after cardiac catheterization. Ann Intern Med 1989;110:119–124.
17.
Rudnick MR, Goldfarb S, Wexler L, et al: Nephrotoxicity of ionic and nonionic contrast media in 1,196 patients: A randomized trial. The Iohexol Cooperative Study. Kidney Int 1995;47:254–261.
18.
Chase GR, Hewett JE: Double sample tests – a distribution free procedure. J Stat Comput Simul 1976;4:117–131.
19.
Mueller C, Buerkle G, Buettner HJ, et al: Prevention of contrast media-associated nephropathy: Randomized comparison of 2 hydration regimens in 1,620 patients undergoing coronary angioplasty. Arch Intern Med 2002;162:329–336.
20.
Solomon R: Contrast-medium-induced acute renal failure. Kidney Int 1998;53:230–242.
21.
McCullough PA, Wolyn R, Rocher LL, Levin RN, O’Neill WW: Acute renal failure after coronary intervention: Incidence, risk factors, and relationship to mortality. Am J Med 1997;103:368–375.
22.
Manske CL, Sprafka JM, Strony JT, Wang Y: Contrast nephropathy in azotemic diabetic patients undergoing coronary angiography. Am J Med 1990;89:615–620.
23.
Fenves AZ, Allgren RL: Radiocontrast dye-induced acute tubular necrosis (ATN): atrial natriuretic peptide versus placebo. J Am Soc Nephrol 1995;6:463.
24.
Levy EM, Viscoli CM, Horwitz RI: The effect of acute renal failure on mortality. A cohort analysis. JAMA 1996;275:1489–1494.
© 2003 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.